Critical Contrast: Mydecine Innovations Group (OTCMKTS:MYCOF) and Intensity Therapeutics (NASDAQ:INTS)

Intensity Therapeutics (NASDAQ:INTS) and Mydecine Innovations Group (OTCMKTS:MYCOF) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Analyst Recommendations

This is a summary of current ratings and target prices for Intensity Therapeutics and Mydecine Innovations Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1	0	3	1	2.80
Mydecine Innovations Group	0	0	0	0	0.00

Intensity Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 66.67%. Given Intensity Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Intensity Therapeutics is more favorable than Mydecine Innovations Group.

Profitability

This table compares Intensity Therapeutics and Mydecine Innovations Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
Mydecine Innovations Group	N/A	N/A	N/A

Earnings and Valuation

This table compares Intensity Therapeutics and Mydecine Innovations Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61 million	($3.57)	-1.18
Mydecine Innovations Group	N/A	N/A	N/A	N/A	N/A

Institutional & Insider Ownership

3.7% of Intensity Therapeutics shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Intensity Therapeutics beats Mydecine Innovations Group on 6 of the 8 factors compared between the two stocks.

About Intensity Therapeutics

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

About Mydecine Innovations Group

Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.